Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients
Purpose The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy. Methods A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizuma...
Gespeichert in:
| Veröffentlicht in: | Journal of gastrointestinal cancer 2019-06, Vol.50 (2), p.214-220 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 220 |
|---|---|
| container_issue | 2 |
| container_start_page | 214 |
| container_title | Journal of gastrointestinal cancer |
| container_volume | 50 |
| creator | Artaç, Mehmet Korkmaz, Levent Coşkun, Hasan Şenol Dane, Faysal Karabulut, Bülent Karaağaç, Mustafa Çabuk, Devrim Karabulut, Senem Aykan, Nuri Faruk Doruk, Hatice Avcı, Nilüfer Turhal, Nazım Serdar |
| description | Purpose
The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy.
Methods
A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels > 30) or non-obese (BMI levels |
| doi_str_mv | 10.1007/s12029-017-0047-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989537121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1989537121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-a8c6889aecea4eeb58d7ed8cafba95111d1fbf51fb1322355567b27bad35655c3</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEYmPwA7igHLkU8tGk6ZFV40PatB3gHCWpizp17UjaSePXk2mwIxfbsl-_sh-Ebil5oIRkj4EywvKE0CwhJM0SdobGNE9pIiWX56eaqRG6CmFNiEwFpZdoxHJOmBJyjFZT2Bk3fNcbY_HC7PEU8BxCwLOqAtfXO8B1i5cWAuAF9Cb0pq8dLrqm83FuGlyY1oHHq9iHtg_X6KIyTYCb3zxBH8-z9-I1mS9f3oqneeJ4mvaJUU4qlRtwYFIAK1SZQamcqazJ45G0pJWtRAyUM8aFEDKzLLOm5EIK4fgE3R99t777GiD0elMHB01jWuiGoGmucsEzymiU0qPU-S4ED5Xe-viv32tK9AGkPoLUEaQ-gNQs7tz92g92A-Vp449cFLCjIMRR-wler7vBt_Hlf1x_AGYyfdo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989537121</pqid></control><display><type>article</type><title>Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients</title><source>SpringerLink Journals - AutoHoldings</source><creator>Artaç, Mehmet ; Korkmaz, Levent ; Coşkun, Hasan Şenol ; Dane, Faysal ; Karabulut, Bülent ; Karaağaç, Mustafa ; Çabuk, Devrim ; Karabulut, Senem ; Aykan, Nuri Faruk ; Doruk, Hatice ; Avcı, Nilüfer ; Turhal, Nazım Serdar</creator><creatorcontrib>Artaç, Mehmet ; Korkmaz, Levent ; Coşkun, Hasan Şenol ; Dane, Faysal ; Karabulut, Bülent ; Karaağaç, Mustafa ; Çabuk, Devrim ; Karabulut, Senem ; Aykan, Nuri Faruk ; Doruk, Hatice ; Avcı, Nilüfer ; Turhal, Nazım Serdar</creatorcontrib><description>Purpose
The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy.
Methods
A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels > 30) or non-obese (BMI levels < 30). Progression-free survival (PFS) and overall survival (OS) were analyzed. Primary tumor location was also investigated in terms of PFS and OS.
Results
The median age of the patients was 59 years. The non-obese group had longer PFS than the obese group (
P
= 0.030). The 2-year survival rate of the non-obese group was also significantly higher (
P
= 0.036). The median PFS of non-obese patients was significantly longer in Kras wild-type patients (10.1 vs. 8.1 months,
P
= 0.010). Among patients with left-sided primary tumor location, median PFS and OS were significantly higher in the non-obese group (PFS non-obese, 11.5 months; obese, 8.8 months;
P =
0.002) (OS non-obese, 29.4 months; obese, 21.4 months;
P =
0.026).
Conclusions
Efficacy of bevacizumab may be lower in obese patients. Among patients with Kras wild-type left-sided tumors treated with bevacizumab-based regimens, the prognosis could be worse for obese patients than that for non-obese patients. There is a need for prospectively designed studies of obese patients to prove the efficacy and dosages of bevacizumab in treatment of mCRC.</description><identifier>ISSN: 1941-6628</identifier><identifier>EISSN: 1941-6636</identifier><identifier>DOI: 10.1007/s12029-017-0047-2</identifier><identifier>PMID: 29302856</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cancer Research ; Gastroenterology ; Internal Medicine ; Medicine ; Medicine & Public Health ; Oncology ; Original Research ; Radiotherapy</subject><ispartof>Journal of gastrointestinal cancer, 2019-06, Vol.50 (2), p.214-220</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-a8c6889aecea4eeb58d7ed8cafba95111d1fbf51fb1322355567b27bad35655c3</citedby><cites>FETCH-LOGICAL-c344t-a8c6889aecea4eeb58d7ed8cafba95111d1fbf51fb1322355567b27bad35655c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12029-017-0047-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12029-017-0047-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29302856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Artaç, Mehmet</creatorcontrib><creatorcontrib>Korkmaz, Levent</creatorcontrib><creatorcontrib>Coşkun, Hasan Şenol</creatorcontrib><creatorcontrib>Dane, Faysal</creatorcontrib><creatorcontrib>Karabulut, Bülent</creatorcontrib><creatorcontrib>Karaağaç, Mustafa</creatorcontrib><creatorcontrib>Çabuk, Devrim</creatorcontrib><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Aykan, Nuri Faruk</creatorcontrib><creatorcontrib>Doruk, Hatice</creatorcontrib><creatorcontrib>Avcı, Nilüfer</creatorcontrib><creatorcontrib>Turhal, Nazım Serdar</creatorcontrib><title>Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients</title><title>Journal of gastrointestinal cancer</title><addtitle>J Gastrointest Canc</addtitle><addtitle>J Gastrointest Cancer</addtitle><description>Purpose
The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy.
Methods
A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels > 30) or non-obese (BMI levels < 30). Progression-free survival (PFS) and overall survival (OS) were analyzed. Primary tumor location was also investigated in terms of PFS and OS.
Results
The median age of the patients was 59 years. The non-obese group had longer PFS than the obese group (
P
= 0.030). The 2-year survival rate of the non-obese group was also significantly higher (
P
= 0.036). The median PFS of non-obese patients was significantly longer in Kras wild-type patients (10.1 vs. 8.1 months,
P
= 0.010). Among patients with left-sided primary tumor location, median PFS and OS were significantly higher in the non-obese group (PFS non-obese, 11.5 months; obese, 8.8 months;
P =
0.002) (OS non-obese, 29.4 months; obese, 21.4 months;
P =
0.026).
Conclusions
Efficacy of bevacizumab may be lower in obese patients. Among patients with Kras wild-type left-sided tumors treated with bevacizumab-based regimens, the prognosis could be worse for obese patients than that for non-obese patients. There is a need for prospectively designed studies of obese patients to prove the efficacy and dosages of bevacizumab in treatment of mCRC.</description><subject>Cancer Research</subject><subject>Gastroenterology</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Radiotherapy</subject><issn>1941-6628</issn><issn>1941-6636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PwzAMhiMEYmPwA7igHLkU8tGk6ZFV40PatB3gHCWpizp17UjaSePXk2mwIxfbsl-_sh-Ebil5oIRkj4EywvKE0CwhJM0SdobGNE9pIiWX56eaqRG6CmFNiEwFpZdoxHJOmBJyjFZT2Bk3fNcbY_HC7PEU8BxCwLOqAtfXO8B1i5cWAuAF9Cb0pq8dLrqm83FuGlyY1oHHq9iHtg_X6KIyTYCb3zxBH8-z9-I1mS9f3oqneeJ4mvaJUU4qlRtwYFIAK1SZQamcqazJ45G0pJWtRAyUM8aFEDKzLLOm5EIK4fgE3R99t777GiD0elMHB01jWuiGoGmucsEzymiU0qPU-S4ED5Xe-viv32tK9AGkPoLUEaQ-gNQs7tz92g92A-Vp449cFLCjIMRR-wler7vBt_Hlf1x_AGYyfdo</recordid><startdate>20190615</startdate><enddate>20190615</enddate><creator>Artaç, Mehmet</creator><creator>Korkmaz, Levent</creator><creator>Coşkun, Hasan Şenol</creator><creator>Dane, Faysal</creator><creator>Karabulut, Bülent</creator><creator>Karaağaç, Mustafa</creator><creator>Çabuk, Devrim</creator><creator>Karabulut, Senem</creator><creator>Aykan, Nuri Faruk</creator><creator>Doruk, Hatice</creator><creator>Avcı, Nilüfer</creator><creator>Turhal, Nazım Serdar</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190615</creationdate><title>Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients</title><author>Artaç, Mehmet ; Korkmaz, Levent ; Coşkun, Hasan Şenol ; Dane, Faysal ; Karabulut, Bülent ; Karaağaç, Mustafa ; Çabuk, Devrim ; Karabulut, Senem ; Aykan, Nuri Faruk ; Doruk, Hatice ; Avcı, Nilüfer ; Turhal, Nazım Serdar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-a8c6889aecea4eeb58d7ed8cafba95111d1fbf51fb1322355567b27bad35655c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer Research</topic><topic>Gastroenterology</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Artaç, Mehmet</creatorcontrib><creatorcontrib>Korkmaz, Levent</creatorcontrib><creatorcontrib>Coşkun, Hasan Şenol</creatorcontrib><creatorcontrib>Dane, Faysal</creatorcontrib><creatorcontrib>Karabulut, Bülent</creatorcontrib><creatorcontrib>Karaağaç, Mustafa</creatorcontrib><creatorcontrib>Çabuk, Devrim</creatorcontrib><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Aykan, Nuri Faruk</creatorcontrib><creatorcontrib>Doruk, Hatice</creatorcontrib><creatorcontrib>Avcı, Nilüfer</creatorcontrib><creatorcontrib>Turhal, Nazım Serdar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastrointestinal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Artaç, Mehmet</au><au>Korkmaz, Levent</au><au>Coşkun, Hasan Şenol</au><au>Dane, Faysal</au><au>Karabulut, Bülent</au><au>Karaağaç, Mustafa</au><au>Çabuk, Devrim</au><au>Karabulut, Senem</au><au>Aykan, Nuri Faruk</au><au>Doruk, Hatice</au><au>Avcı, Nilüfer</au><au>Turhal, Nazım Serdar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients</atitle><jtitle>Journal of gastrointestinal cancer</jtitle><stitle>J Gastrointest Canc</stitle><addtitle>J Gastrointest Cancer</addtitle><date>2019-06-15</date><risdate>2019</risdate><volume>50</volume><issue>2</issue><spage>214</spage><epage>220</epage><pages>214-220</pages><issn>1941-6628</issn><eissn>1941-6636</eissn><abstract>Purpose
The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy.
Methods
A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels > 30) or non-obese (BMI levels < 30). Progression-free survival (PFS) and overall survival (OS) were analyzed. Primary tumor location was also investigated in terms of PFS and OS.
Results
The median age of the patients was 59 years. The non-obese group had longer PFS than the obese group (
P
= 0.030). The 2-year survival rate of the non-obese group was also significantly higher (
P
= 0.036). The median PFS of non-obese patients was significantly longer in Kras wild-type patients (10.1 vs. 8.1 months,
P
= 0.010). Among patients with left-sided primary tumor location, median PFS and OS were significantly higher in the non-obese group (PFS non-obese, 11.5 months; obese, 8.8 months;
P =
0.002) (OS non-obese, 29.4 months; obese, 21.4 months;
P =
0.026).
Conclusions
Efficacy of bevacizumab may be lower in obese patients. Among patients with Kras wild-type left-sided tumors treated with bevacizumab-based regimens, the prognosis could be worse for obese patients than that for non-obese patients. There is a need for prospectively designed studies of obese patients to prove the efficacy and dosages of bevacizumab in treatment of mCRC.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29302856</pmid><doi>10.1007/s12029-017-0047-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-6628 |
| ispartof | Journal of gastrointestinal cancer, 2019-06, Vol.50 (2), p.214-220 |
| issn | 1941-6628 1941-6636 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989537121 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Cancer Research Gastroenterology Internal Medicine Medicine Medicine & Public Health Oncology Original Research Radiotherapy |
| title | Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A35%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bevacuzimab%20May%20Be%20Less%20Effective%20in%20Obese%20Metastatic%20Colorectal%20Cancer%20Patients&rft.jtitle=Journal%20of%20gastrointestinal%20cancer&rft.au=Arta%C3%A7,%20Mehmet&rft.date=2019-06-15&rft.volume=50&rft.issue=2&rft.spage=214&rft.epage=220&rft.pages=214-220&rft.issn=1941-6628&rft.eissn=1941-6636&rft_id=info:doi/10.1007/s12029-017-0047-2&rft_dat=%3Cproquest_cross%3E1989537121%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1989537121&rft_id=info:pmid/29302856&rfr_iscdi=true |